Showing the first 10 of 418 rows. Increase the table's page_size to embed more in the static export.
age
f64
albumin
f64
alk.phos
f64
ascites
i64
ast
f64
bili
f64
chol
u64
copper
u64
edema
f64
hepato
u64
id
u64
platelet
u64
protime
f64
sex
str
spiders
u64
stage
u64
status
u64
time
u64
trig
u64
trt
u64
58.7652292950034
2.60
1,718.0
1
137.95
14.5
261
156
1.0
1
1
190
12.2
f
1
4
2
400
172
1
56.4462696783025
4.14
7,394.8
0
113.52
1.1
302
54
0.0
1
2
221
10.6
f
1
3
0
4,500
88
1
70.0725530458590
3.48
516.0
0
96.10
1.4
176
210
0.5
0
3
151
12.0
m
0
4
2
1,012
55
1
54.7405886379192
2.54
6,121.8
0
60.63
1.8
244
64
0.5
1
4
183
10.3
f
1
4
2
1,925
92
1
38.1054072553046
3.53
671.0
0
113.15
3.4
279
143
0.0
1
5
136
10.9
f
1
3
1
1,504
72
2
66.2587268993840
3.98
944.0
0
93.00
0.8
248
50
0.0
1
6
None
11.0
f
0
3
2
2,503
63
2
55.5345653661875
4.09
824.0
0
60.45
1.0
322
52
0.0
1
7
204
9.7
f
0
3
0
1,832
213
2
53.0568104038330
4.00
4,651.2
0
28.38
0.3
280
52
0.0
0
8
373
11.0
f
0
3
2
2,466
189
2
42.5078713210130
3.08
2,276.0
0
144.15
3.2
562
79
0.0
0
9
251
11.0
f
1
2
2
2,400
88
1
70.5598904859685
2.74
918.0
1
147.25
12.6
200
140
1.0
0
10
302
11.5
f
1
4
2
51
143
2
418 rows, 20 columns
No selection
No selection
SELECT * FROM data
Primary biliary cholangitis is an autoimmune disease leading to destruction of the small bile ducts in the liver. Progression is slow but inexhortable, eventually leading to cirrhosis and liver decompensation. The condition has been recognised since at least 1851 and was named "primary biliary cirrhosis" in 1949. Because cirrhosis is a feature only of advanced disease, a change of its name to "primary biliary cholangitis" was proposed by patient advocacy groups in 2014.This data is from the Mayo Clinic trial in PBC conducted between 1974 and 1984. A total of 424 PBC patients, referred to Mayo Clinic during that ten-year interval, met eligibility criteria for the randomized placebo controlled trial of the drug D-penicillamine. The first 312 cases in the data set participated in the randomized trial and contain largely complete data. The additional 112 cases did not participate in the clinical trial, but consented to have basic measurements recorded and to be followed for survival. Six of those cases were lost to follow-up shortly after diagnosis, so the data here are on an additional 106 cases as well as the 312 randomized participants.Variable description:
age: in years
albumin: serum albumin (g/dl)
alk.phos: alkaline phosphotase (U/liter)
ascites: presence of ascites
ast: aspartate aminotransferase, once called SGOT (U/ml)
bili: serum bilirunbin (mg/dl)
chol: serum cholesterol (mg/dl)
copper: urine copper (ug/day)
edema: 0 no edema, 0.5 untreated or successfully treated 1 edema despite diuretic therapy
hepato: presence of hepatomegaly or enlarged liver
id: case number
platelet: platelet count
protime: standardised blood clotting time
sex: m/f
spiders: blood vessel malformations in the skin
stage: histologic stage of disease (needs biopsy)
status: status at endpoint, 0/1/2 for censored, transplant, dead
time: number of days between registration and the earlier of death, transplantion, or study analysis in July, 1986
trt: 1/2/NA for D-penicillmain, placebo, not randomised
trig: triglycerides (mg/dl)
Source:
T Therneau and P Grambsch (2000), Modeling Survival Data: Extending the Cox Model, Springer-Verlag, New York. ISBN: 0-387-98784-3.
